U.S. Opium and Cannabis API Market

The U.S. opium and cannabis API market is estimated to be valued at USD 6,832.0 Mn in 2026 and is expected to reach USD 17,863.8 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 14.7% from 2026 to 2033. In the U.S., the opium and cannabis active pharmaceutical ingredient (API) industry represents a highly specific and fast-growing sector. In the case of opium-based APIs, medicines like thebaine, oxycodone, codeine, and morphine are still a mainstay in the treatment of pain symptoms. On the other hand, the adoption of plant-based active ingredients derived from cannabis like cannabidiol (CBD) and tetrahydrocannabinol (THC) in treatment for multiple sclerosis, chronic pain, epilepsy, anxiety and other neurological health concerns is on the increase. The market is shaped by a complex regulatory framework governed by the U.S. Drug Enforcement Administration (DEA), the U.S. Food and Drug Administration (FDA), and evolving state-level cannabis policies. Rising acceptance of plant-based therapeutics, growing pharmaceutical R&D investments, and an expanding regulatory pathway for cannabinoid-based medicines are driving the commercialization and adoption of opium and cannabis APIs across the U.S. pharmaceutical manufacturing sector. Market Dynamics The U.S. opium and cannabis API market is primarily driven by the increasing incidence of chronic pain, neurological diseases, epilepsy and cancer associated diseases that require an upward spiraling need for plant-derived pharmaceutical grade APIs. FDA approved cannabis products, escalating investments made in high grade plant cultivation, efficient extraction and purification processes and growing R&D initiatives have led to the quicker commercialization of cannabis and opium derived APIs. However, the growth of the market is limited by factors such as stringent federal regulations under the Controlled Substances Act (CSA), complex licensing requirements, and concerns surrounding opioid misuse and abuse. Nevertheless, there are abundant growth prospects due to factors such as expanding medical cannabis adoption, progressive legalization initiatives, increasing global demand for high-quality U.S.-manufactured APIs, and technological advancements such as AI-enabled process optimization and green chemistry. Key Features of the Study • This report provides in-depth analysis of the U.S. opium and cannabis API market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the U.S. opium and cannabis API market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Mallinckrodt Pharmaceuticals, Alcaliber S.A., Johnson Matthey Plc, Noramco, Inc., Cambrex Corporation, Alps Pharmaceutical Ind. Co., Ltd., EuroAPI, Purisys LLC, Catalent, Inc., and MediPharm Labs Corp. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The U.S. opium and cannabis API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. opium and cannabis API market Market Segmentation • API Type Insights (Revenue, USD Mn, 2021 - 2033) o Opium o Cannabis • End User Insights (Revenue, USD Mn, 2021 - 2033) o Biopharmaceutical Companies o Research Institutes • Key Players Insights o Mallinckrodt Pharmaceuticals o Alcaliber S.A. o Johnson Matthey Plc o Noramco, Inc. o Cambrex Corporation o Alps Pharmaceutical Ind. Co., Ltd. o EuroAPI o Purisys LLC o Catalent, Inc. o MediPharm Labs Corp.